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Abstract
Background: Giant cell myocarditis, characterized by infiltration of multinucleated giant cells in the myocardium, is
a rare type of myocarditis. It often progresses rapidly into fulminant heart failure and indicates a poor prognosis.
When a patient with giant cell myocarditis develops into severe myocarditis presenting with a cardiogenic shock,
we should use a percutaneous cardiopulmonary support (PCPS), which could occur complications. We experienced
a patient with giant cell myocarditis, who developed left ventricular thrombus formations during the circulation
support therapy with PCPS for cardiogenic shock.
Case presentation: A 60-year-old man who developed a cardiogenic shock was transferred to our hospital. After the
admission, inotropic agents were increased and an intra-aortic balloon pumping was started. But these therapies did not
improve his hemodynamic status. He was placed PCPS. Then, he underwent endomyocardial biopsy and was diagnosed
with giant cell myocarditis. On the next morning, he developed complete atrioventricular block, and subsequently,
thrombus formations occurred in his left ventricular outlet tract and Valsalva sinus despite an anticoagulant therapy.
Thereafter, we intensified the anticoagulant therapy to prevent further thrombus formation, but he developed an
intracranial hemorrhage. He did not recover from heart failure and died 16 days after the admission.
Conclusions: We present a patient with giant cell myocarditis who developed widespread thrombosis in the
left ventricle during the circulatory support with PCPS, despite anticoagulant therapy. In this case, decreased
left myocardial contractility caused by giant cell myocarditis and increased left ventricular afterload by the
retrograde perfusion from the PCPS induced the thrombotic tendency and congestion in the left ventricle. In
addition, he developed complete atrioventricular block, which reduced the left ventricular ejection and enhanced the
thrombus formation. Because patients with giant cell myocarditis have a low probability of spontaneous recovery, heart
transplantation or ventricular assist device implantation may be required for circulatory support. We should establish
mechanical circulatory support rapidly to improve the prognosis of patients with giant cell myocarditis. Moreover, a
ventricular assist device, which can prevent both ventricular congestion and retrograde blood flow, might be suitable
to prevent complications as this case.
Keywords: Giant cell myocarditis, Ventricular thrombus, Percutaneous cardiopulmonary support system
* Correspondence: y-takei@xf7.so-net.ne.jp
1Department of Anesthesiology, Tohoku University Hospital, 1-1 Seiryomachi,
Aoba-ku, Sendai 980-8574, Japan
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Takei et al. JA Clinical Reports  (2016) 2:41 
DOI 10.1186/s40981-016-0067-0
Background
Giant cell myocarditis, characterized by infiltration of
multinucleated giant cells in the myocardium, is a rare
type of myocarditis. Fulminant myocarditis can occur
during its clinical course. When it occurs, prognosis is ex-
tremely poor due to acute heart failure [1–4]. Herein, we
report a patient with giant cell myocarditis who developed
massive left ventricular thrombus during the circulatory
support with percutaneous cardiopulmonary support
(PCPS) for the treatment of progressive heart failure.
Case presentation
A 60-year-old man noted cold-like symptoms. After a
month, he was visited to a local hospital and was sus-
pected with myocarditis because his blood examination
showed high inflammatory reactions and his echocardio-
gram showed severe cardiac dysfunction. He was started
on intravenous continuous infusions of dobutamine
(5 μg/kg/min) and dopamine (5 μg/kg/min) and trans-
ferred to our hospital. Upon admission to the intensive
care unit, his consciousness, heart rate, blood pressure,
arterial oxygen saturation level (5 L/min of supplemental
oxygen via facemask), and body temperature were clear,
105 bpm, 105/66 mmHg, 100%, and 38.2 °C, respectively.
His chest radiograph and chest computed tomography
showed pulmonary congestion and bilateral pleural effu-
sion without cardiomegaly, and the electrocardiogram
showed low voltage of R-wave and intraventricular con-
duction disturbance in all leads (Fig. 1). His laboratory
examination showed inflammatory reaction, elevated levels
of cardiac enzyme, and serum brain natriuretic peptide but
almost normal range of coagulation (Table 1). His transtho-
racic echocardiogram showed a significant decrease in the
myocardial contractility of the both ventricles but did not
show the enlargement of both ventricles and a thrombus
formation in all ventricles. Right cardiac catheterization,
under the continuous infusions of dopamine (5 μg/kg/min)
and dobutamine (5 μg/kg/min), showed that cardiac output
(CO), pulmonary arterial pressure (PAP), pulmonary
arterial wedge pressure, and mixed venous oxygenation
saturation (SvO2) were 3.60 L/min, 37/18(26) mmHg,
26 mmHg, and 40%, respectively, which indicated cardio-
genic shock and post-capillary pulmonary hypertension
(Table 2). Coronary angiography showed no abnormal
findings. Because he was diagnosed with myocarditis and
refractory to inotropic agents, he was inserted with intra-
aortic balloon pumping (IABP). Despite 6 h of IABP
support, his hemodynamic status progressively deteriorated;
hence, we decided to start the mechanical ventilation and
mechanical circulatory support by a PCPS on him. We ad-
ministered 1 mg of midazolam, 0.2 mg of fentanyl, and
50 mg of rocuronium, performed endotracheal intubation,
and started the airway pressure release ventilation with
fraction of inspired oxygen (FIO2) of 0.6, the high con-
tinuous airway pressure (CPAP) of 20 cmH2O, duration
of high CPAP of 9.5 s, low CPAP of 0 cmH2O, and dur-
ation of low CPAP of 0.5 s in order to avoid the lung
collapse. In this setting, his minute ventilation volume
Fig. 1 The 12-lead electrocardiogram of the patient upon admission to the intensive care unit. Sinus rhythm, low-voltage R-wave, and intraventricular
conduction disturbance in all leads were seen
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was 2.4 L (approximately 400 mL of tidal volume and
6/min of respiratory rate). After the initiation of the
mechanical ventilation, his arterial blood gas analysis
from the right radial artery showed a pH of 7.499, arter-
ial oxygen tension (PaO2) of 153 mmHg, and arterial
carbon dioxide (CO2) tension (PaCO2) of 34.8 mmHg.
And we started continuous infusion of propofol (1–
2.5 mg/kg/h) and fentanyl (40 μg/h) for sedation. Then,
we administered heparin (7000 IU) as an intravenous
bolus, and his activated clotting time (ACT) was pro-
longed to 198 s. We placed a venous cannula into the
right atrium via the common right femoral vein and an
arterial cannula into the left femoral artery and started
the PCPS.
At the initiation of PCPS, the target value of PCPS
blood flow was set at 3.0 L/min (rotation speed of
3000 rpm), and the FIO2 and total gas flow of the mem-
brane oxygenator were set at 0.6 and 1 L/min,
respectively.
And the intravenous continuous infusion of heparin
(10,000 IU/day) was started in order to maintain his
ACT within the range of 150 to 200 s. After the PCPS
blood flow reached to 3.0 L/min, the SvO2 increased to
66% and the total blood flow, which was the sum of
PCPS blood flow and his own cardiac output, increased
from 3.0 to 5.3 L/min (Table 2).
Subsequently, we performed endomyocardial biopsy
(EMB) followed by rapid microscopic examination,
which showed the characteristic infiltration of multinu-
cleated giant cells in the myocardium. He was eventually
diagnosed with giant cell myocarditis (Fig. 2).
On the next morning, he developed complete atrio-
ventricular block (Fig. 3), subsequent decreased blood
pressure from 100/50 to 70/40 mmHg, and increased
pulmonary arterial pressure from 35/15 to 60/20 mmHg.
In addition, sudden elevation of PaCO2 from 31 to
62.5 mmHg was also observed despite the preservation
of both the steady PCPS output and the mechanical
ventilation setting (Fig. 4 and Table 2). Hence, we per-
formed transesophageal echocardiography (TEE), which
indicated widespread thrombus formations and marked
congestion in his left ventricular outlet tract and Valsalva
sinus and closure of the aortic valve; however, there is
no thrombus in his right ventricle (Fig. 5). Then, we
checked ACT, which was 168 s, and performed an add-
itional test for heparin-induced thrombocytopenia (HIT)
antibody, which we learned of the negative result later.
We increased the PCPS blood flow up to 3.5 L/min
and total gas flow up to 4.0 L/min, which lead to success
of CO2 excretion, but his hemodynamic status remained
unstable. After that, we started temporary cardiac pacing
to treat complete atrioventricular block, which restored
Table 1 The blood examination on admission and 1 and 10 days after the admission
Admission 1 day after the admission
(after PCPS placement)
10 days after the admission
(after intensive anticoagulant therapy)
White blood cell counts (/μL) 9200 9100 12,400
Hemoglobin (g/dL) 10.2 10.6 10.7
Platelet counts (×104/μL) 38.2 29.3 27.6
Total bilirubin (mg/dL) 0.8 0.7 1.5
Aspartate transaminase (IU/L) 401 431 194
Alanine aminotransferase (IU/L) 403 367 236
Lactate dehydrogenase (IU/L) 1081 926 932
Blood urea nitrogen (mg/dL) 18 17 15
Creatinine (mg/dL) 1.18 1.01 0.94
C-reactive protein (mg/dL) 13.2 10.9 17.1
Creatine kinase (IU/L) 1194 776 871
Creatine kinase-MB (IU/L) 32 32 39
Troponin T (ng/dL) 5.19 – –
Brain natriuretic peptide (pg/mL) 3035 2266 –
Lactate (mmol/L) 1.20 1.12 0.97
BE (mmol/L) −0.2 −0.1 −1.3
International normalized ratio of prothrombin time 1.14 1.16 1.21
Activated partial thromboplastin time (s) 30.0 38.7 118.9
Activated clotting time (s) 140 198 273
Almost the normal ranges of coagulation test were found on admission. The marked prolonged activated partial thromboplastin time and activated clotting time
were found after the intensive anticoagulation therapy for the intraventricular thrombus
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Fig. 2 Microscopic examination from the endomyocardial biopsy of the right ventricle. Characteristic infiltrations of multinucleated giant cells in
the myocardium (open circle) were seen
Table 2 Hemodynamic status of the patient on admission, before and after the initiation of PCPS, after the onset of complete
atrioventricular block, and after ventricular pacing
Admission Before initiation
of PCPS
Initiation of PCPS Onset of
complete AVB
After ventricular pacing




APRV, FIO2 = 0.6,
Phigh = 20 cm H2O,
Thigh = 9.5 s, Plow = 0 cm
H2O, Tlow = 0.5 s
Same as on the left APRV, FIO2 = 0.6,
Phigh = 15 cm H2O,
Thigh = 5.5 s, Plow = 0 cm
H2O, Tlow = 0.5 s
pH 7.531 7.532 7.449 7.272 7.554
SaO2 (%) 95.1 97.0 98.5 95.7 98.5
PaO2 (mmHg) 75.4 97.0 153.0 100.8 158.0
PaCO2 (mmHg) 25.5 28.1 34.8 62.5 27.3
EtCO2 (mmHg) – – 21 41 17
BE (mmol/L) −0.2 1.7 −0.1 0.3 1.9
Lac (mmol/L) 1.2 1.3 1.12 1.03 1.28
ABP (mmHg) 110/55 112/42 97/41 70/40 136/37
PAP (mmHg) 37/18 (26) 28/11 19/10 60/20 18/13
PAWP (mmHg) 25 – 12 30 –
RAP (mmHg) 18 18 12 18 8
CO (L/min) 3.60 3.80 2.3 <<1.0 1.3
Output of PCPS (L/min) – – 3.0 3.0 3.5
The sum of PCPS blood flow and
his own cardiac output (L/min)
3.60 3.80 5.3 3.0 4.8
Total gas flow of oxygenator (L/min) – – 1.0 1.0 4.0
SvO2 (%) 40 39.7 66 55 69
The cardiogenic shock was improved by the PCPS support. After the onset of complete AV block, significant decrease of CO, pulmonary congestion, and increased
PaCO2 were observed
PCPS percutaneous cardiopulmonary support, AVB atrioventricular block, APRV airway pressure release ventilation, FIO2 fraction of inspired oxygen, Phigh high
continuous positive airway pressure, Thigh duration of Phigh, Plow low continuous positive airway pressure, Tlow duration of Plow, EtCO2 end-tidal carbon dioxide
tension, PaCO2 arterial carbon dioxide tension, ABP arterial blood pressure, PAP pulmonary artery pressure, PAWP pulmonary artery wedge pressure, RAP right atrial
pressure, CO cardiac output, SvO2 mixed venous oxygenation saturation
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his left ventricular contractility, opened the aortic valve,
and subsequently washed out the thrombus.
Thereafter, for the purpose of preventing further
thrombus formation, anticoagulant therapy was intensi-
fied (20,000 IU/day of heparin) to maintain ACT within
the range of 200 to 240 s. Ten days after the admission,
his ACT was markedly prolonged up to 273 s (Table 2)
and he presented with an anisocoria. Therefore, we per-
formed a computed tomography (CT) scan of the brain,
which revealed the intracranial hemorrhage. He did not
recover from the heart failure and died 16 days after the
admission.
Discussion
Giant cell myocarditis is characterized by infiltration of
multinucleated giant cells in the myocardium and distin-
guished from cardiac sarcoidosis by the absence of non-
caseous necrosis. Cardiac sarcoidosis is generally associated
with extracardiac lesions and progresses slowly, whereas
giant cell myocarditis develops and progresses to heart fail-
ure rapidly, which results in poor prognosis [1–3]. An ac-
curate data about the morbidity of giant cell myocarditis
has not been shown because the pathological diagnosis of
the disease is difficult. However, approximately 100 cases
were reported despite the rarity of this myocarditis type
Fig. 3 Electrocardiogram strips on the next morning. Complete atrioventricular block was seen
Fig. 4 The change in the hemodynamic status around the onset of the atrioventricular block. HR heart rate, ABP arterial blood pressure, PAP
pulmonary artery pressure, PEtCO2 end-tidal carbon dioxide tension, PaCO2 arterial carbon dioxide tension, SvO2 mixed venous oxygenation
saturation, PCPS percutaneous cardiopulmonary support, CO cardiac output. ① The onset of the complete atrioventricular block. ② The
start of the ventricular pacing. After the onset of the complete atrioventricular block, the decrease of BP and the increase of PAP and
PaCO2 continued until the point when the blood flow and the gas flow of the PCPS were augmented. The hemodynamics of the patient
improved along with the recovery of the ventricular contraction by the ventricular pacing
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[4]. Mechanical circulatory support, such as IABP and/or
PCPS as well as inotropes, is required for the treatment of
acute giant cell myocarditis because the disease often
progresses to fulminant myocarditis. Some reports showed
the efficacy of immunosuppressive therapy for giant cell
myocarditis, which suggested a relationship between giant
cell myocarditis and autoimmune reaction [5–7]. In
addition, a multicenter study of immunosuppressive ther-
apy for giant cell myocarditis showed the prolonged me-
dian transplant-free survival from 3 to 12.3 months [1].
However, some studies also showed that few patients re-
covered from heart failure and weaned from mechanical
circulatory support [7–9]. The patients of that study even-
tually required heart transplantation or circulatory support,
such as ventricular assist device (VAD) for destination
therapy. In Japan, VAD is a practical option for the rescue
treatment of chronic giant cell myocarditis because only 40
heart transplantations are performed per year, and the
mean waiting period for transplantation is 636 days. We
need to transfer the patients to the hospital capable for left
VAD (LVAD) surgery, which is limited in Japan, if needed
for LVAD placement.
We could not save this patient because of the disease
progression and the complications, including the throm-
bosis due to the congestion of the left ventricle and
intracranial hemorrhage due to the intensive anticoagu-
lant therapy to prevent thrombosis.
Myocarditis alone rarely accompanies ventricular
thrombosis unlike dilated cardiomyopathy. Left ventricu-
lar distension strongly contributes to intraventricular
thrombosis. Therefore, the cornerstone in prevention of
intraventricular thrombosis is systemic anticoagulant
therapy and prevention of left ventricular distension. In
this case, thrombotic tendency was induced by the left
ventricular congestion due to decreased left myocardial
contractility. Regardless of promoting the left ventricular
ejection by inotropic agents and IABP, adequate cardiac
output was not obtained, which resulted in the place-
ment of PCPS. However, peripheral PCPS perfused the
aortic root retrogradely, which caused the increase of left
ventricular afterload, the subsequent distension of the
left ventricle, and the further increase of thrombotic ten-
dency and congestion at the left ventricular outlet tract.
Approximately 15% of patients with giant cell myocardi-
tis are associated with atrioventricular block [1, 4]. In
this case, the complete atrioventricular block induced a
critical decrease of the left ventricular ejection, which re-
sulted in the further left ventricle distension, which
might trigger the thrombosis (Fig. 6).
Before the onset of the atrioventricular block, the pa-
tient had 2.3 L/min of the pulmonary circulation with
2.4 L/min of minute volume of ventilation and 3.0 L/min
of the PCPS blood flow with 1 L/min of gas flow of the




Fig. 5 Transesophageal echocardiography (TEE) after the onset of atrioventricular block. a Mid-esophageal 4-chamber (ME 4ch) view showed
thrombus formations and congestion in the left ventricle. b Mid-esophageal aortic valve short-axis (ME AV SAX) view showed thrombus formations in
the Valsalva sinus and aortic valve closure. c Mid-esophageal long-axis (ME AV LAX) view showed thrombus formations in the left ventricular tract and
the Valsalva sinus
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CO2 elimination was thought to be the pulmonary circula-
tion. After the onset of the atrioventricular block, the pul-
monary circulation decreased to far less than 1.0 L/min
because of the loss of the cardiac output while 3.0 L/min
of the PCPS blood flow was maintained. Hence, the total
lung blood flow decreased to approximately 3.0 L/min,
and the artificial lung ought to excrete almost whole CO2.
However, the gas flow of the artificial lung remained
1.0 L/min, which might be too little to excrete sufficient
amount of the CO2. Thereafter, the PaCO2 of the patient
rose from 34.8 to 62.5 mmHg.
To our knowledge, no guideline is available for treatment
of intraventricular thrombosis in PCPS patients. The treat-
ment choices are thrombectomy and intensive anticoagu-
lant therapy [10–12]. Because of the unstable circulatory
status of the patient, intensive systemic anticoagulant ther-
apy and temporary cardiac pacing, which could recover the
ventricular contractility and ejection, were the possible
choices. Therefore, we started temporary cardiac pacing,
which recovered the left ventricular contractility, opened
the aortic valve, and washed out the thrombi. Additionally,
the efficacy of local thrombolysis in intraventricular throm-
bosis was recently reported. This technique might be
effective in this case [13].
The washed out thrombi formed at the onset of the
complete atrioventricular block could cause cerebral in-
farctions, and the intensified coagulation therapy might
deteriorate the cerebral infarctions into the intracranial
hemorrhage. At the onset of complete atrioventricular
block, we did not perform a CT scan of the brain or
awaken him from the deep sedation due to his unstable
circulatory status. But 10 days after the admission, we
performed a CT scan of the brain at the risk of circu-
latory failure because the patient presented with an
anisocoria. However, we could not identify the true
pathogenesis of the intracranial hemorrhage.
Different types of myocarditis show different clinical
courses and prognoses and require different treatments.
Therefore, EMB, identifying the histological type of myo-
carditis, should be performed as the patient’s condition
permits. In this case, multidrug immunosuppressive ther-
apy was started after the histological diagnosis of giant cell
myocarditis. However, as previously described, heart
transplantation or VAD may be required for a definitive
therapy within months or years. LVAD, withdrawing the
blood from the left ventricular apex and returning the
blood to the ascending aorta, can establish physiological
perfusion and reduce left ventricular volume, whereas per-
ipheral PCPS perfuses aorta retrogradely, increases left
ventricular afterload, and might induce left ventricular dis-
tension. In addition, LVAD can cause less bleeding com-
plications than PCPS because LVAD requires weaker
anticoagulation than PCPS [14]. If we could place an
LVAD on the patient at the diagnosis of giant cell myocar-
ditis, complications such as thrombosis and bleeding
might be prevented, which might result in smooth bridge
to heart transplantation. To improve the prognosis of
myocarditis, full knowledge of the clinical course of myo-
carditis, precise diagnosis, transfer to an advanced medical
center where LVAD placement can be performed and
rapid establishment of adequate mechanical circulatory
support should be required.
Fig. 6 The mechanism of thrombus formation in this case. PCPS percutaneous cardiopulmonary support, AV-block atrioventricular block, BP
systemic blood pressure, PAP pulmonary artery pressure, PaCO2 arterial carbon dioxide tension. Giant cell myocarditis induced the left ventricular
distension and subsequent thrombus formation tendency. The retrograde perfusion by the PCPS and the complete atrioventricular block further
enhanced thrombus formation tendency. As a result, widespread thrombi were formed in the left ventricular tract and the Valsalva sinus
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Conclusions
We present a patient with giant cell myocarditis who
developed widespread thrombosis in the left ventricle
during PCPS support. Retrograde perfusion by PCPS and
complete atrioventricular block promoted left ventricular
distension, reduced left ventricular ejection, and caused
widespread thrombosis. In the circulation management of
patients with giant cell myocarditis, we should rapidly
establish physiological mechanical circulatory support.
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